CAS: 905586-69-8; (S)-5-Fluoro-2-((1-(4-Fluorophenyl)Ethyl)Amino)-6-((5-Methyl-1H-Pyrazol-3-yl)Amino)Nicotinonitrile

上下游产品

2,5-difluoro-6-(5-methyl-1H-pyrazol-3-ylamino)nicotinonitrile (S)-1-(4-Fluoro-phenyl)-ethylamine (S)-1-(4-fluorophenyl)ethan-1-aminium chloride

2,5-Difluoro-6-(5-Methyl-1H-Pyrazol-3-Ylamino)Nicotinonitrile,(S)-(-)-1-(4-氟苯基)乙胺置于n,N-二异丙基乙胺体系中,用 正丁醇 作为反应溶剂,化学反应 18.0H,以91%的收率获得产物5-氟-2-[[(1S)-1-(4-氟苯基)乙基]氨基]-6-[(5-甲基-1H-吡唑-3-基)氨基]-3-吡啶腈
参考文献:Wo2006/82392
标题:Wo2006/82392

专利信息

专利号:US-11285169-B2
优先权日:2013-03-13
标题 :Methods for modulating chemotherapeutic cytotoxicity
发明人：ROBERTS DAVID D; SOTO PANTOJA DAVID R
权利人:US HEALTH
摘要:Methods of reducing cytotoxicity of a chemotherapeutic agent to non-cancer cells by administering to a subject with cancer an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent, such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are provided. Example disclosed methods reduce cardiotoxicity. In one example, the methods include administering to a subject with cancer an effective amount of a CD47 antisense morpholino oligonucleotide and an anthracycline such as doxorubicin. Methods of increasing cytotoxicity of a chemotherapeutic agent in cancer cells by administering to a subject with a tumor an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are also provided. In some embodiments, the inhibitor of CD47 signaling is administered to the subject before, during, or after the administration of the DNA damaging agent.